Bryn Mawr Skin & Cancer Institute Bryn Mawr Skin & Cancer Institute
Cirillo Cosmetic Dermatology Spa Cirillo Cosmetic Dermatology Spa
Cirillo Center for Plastic Surgery Cirillo Center for Plastic Surgery

Curriculum Vitae

Stuart Robert Lessin, M.D.

Current Position: Staff Dermatologist

Bryn Mawr Skin & Cancer Institute


Bryn Mawr Office

Rosemont Business Campus
919 Conestoga Road
Building Two, Suite 106
Bryn Mawr, PA 19010


Newtown Square Office

Main Line Health at Newtown Square
3855 West Chester Pike
Suite 325
Newtown Square, PA 19073

Phone 610.525.5028
Fax 610.525.2494

Education:

1982
M.D.
Temple University School of Medicine, Philadelphia, Pennsylvania
1977
B.S.
Pennsylvania State University, University Park, Pennsylvania

Training and Fellowship Experience:

1986-1987
Research Fellow, The Wistar Institute, Philadelphia, PA
1985-1986
Chief Resident, Depart. of Derm., Univ. of Penna., Phila., PA
1983-1985
Resident, Depart. of Derm., Univ. of Penna., Phila., PA
1982-1983
Intern in Internal Medicine, Albert Einstein Medical Center, Phila., PA
1977-1980
Research Assistant, Department of Physiology and Biophysics, Temple University Health Science Center, Philadelphia, PA

Faculty Appointments:

2010-2011
Professor Emeritus, Fox Chase Cancer Center
2008-2010
Professor of Medicine (Dermatology), Fox Chase Cancer Center
2000-2008
Senior Member (Professor), Fox Chase Cancer Center, Phila., PA
2000-2010
Professor, Department of Medicine (in Dermatology), Temple University School of Medicine, Phila., PA.
1998-2000
Associate Professor, Department of Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine
1997
Visiting Scientist, Wyeth-Lederle Vaccines-Malvern, PA (6mo Sabbatical)
1996-2000
Associate Professor, Department of Dermatology, University of Pennsylvania School of Medicine
1995-1998
Staff Physician, Philadelphia Veterans Affairs Medical Center
1991-1995
Research Associate, Philadelphia Veterans Affairs Medical Center
1987-1996
Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine
1987-2010
Associate Scientist, Wistar Institute, Philadelphia, PA

Hospital Affiliations:

2011
Bryn Mawr Hospital, Bryn Mawr, PA
2000-2010
Fox Chase Cancer Center, Philadelphia, PA
2000-2010
Temple University Hospital, Philadelphia, PA
1995-1998
Philadelphia Veterans Affairs Medical Center, Philadelphia, PA
1987-2000
Hospital of the University of Pennsylvania, Philadelphia, PA

Hospital and Administrative Appointments:

2000-2010
Director of Dermatology, Fox Chase Cancer Center
2000-2010
Chief, Div. of Dermatology, Depart. of Medicine, Temple Univ. Hospital
2001-2009
Director, FCCC Melanoma Family Risk Assessment Program
1998-2000
Director, Melanoma Core Facility, Univ. of Pennsylvania Cancer Center
1998-2000
Co-Director - Pigmented Lesion Group, Depart of Derm., Univ. of Pa.
1992-1998
Director, Molecular Diagnostic Laboratory, Depart of Derm., Univ. of Pa.
1990-2000
Co-Director - Cutaneous Lymphoma Program, Depart. of Derm., U. of Pa.
1987-2000
Chairman, Residency Selection Committee, Depart. of Derm., Univ. of Pa.

Hospital Committees:

2001-2009
Compliance Committee, Fox Chase Cancer Center (member)
2002-2010
Patient Safety Committee, Fox Chase Cancer Center (member)
2002-2010
Biorepository & Tissue Bank Facility Advisory Committee, Fox Chase Cancer Center (member)
2002-2010
Translational Research Laboratory Facility Advisory Committee, Fox Chase Cancer Center (member)
2009-2010
Continuing Medical Education Committee, FCCC (member)
2009-2010
Executive Compliance Committee, Fox Chase Cancer Center (member)

Specialty Certification:

American Board of Dermatology (1986)

Licensure:

Pennsylvania MD029219E
New Jersey 45327

Honors and Awards:

2005
America's Top Doctors for Cancer (1st -8th editions, 2005-2013)
2004
Best Doctors in America (2005-2010)
2003
America's Top Doctors (3rd – 13th editions, 2003-2014)
2002
Dermatology Program Development Award, Dermatology Foundation
1999
Mid-Career Development Award, National Institutes of Health
1991
FIRST Award, National Institutes of Health
1991
Career Development Award, Department of Veterans Affairs
1990
Career Development Award, Dermatology Foundation
1986
Physician Scientist Award, National Institutes of Health
1986
Research Fellowship, Dermatology Foundation
1980
International Travel Award, National Science Foundation

Memberships in Professional and Scientific Societies:

International Society for Cutaneous Lymphomas (Member)

United States Cutaneous Lymphoma Consortium (Member)

American Dermatological Association (Member)

American Academy of Dermatology (Fellow)

Society for Investigative Dermatology (Member)

American Contact Dermatitis Society (Fellow)

Dermatology Foundation Annenberg Circle (Sustaining Member)

Pennsylvania Medical Society (Member)

Pennsylvania Academy of Dermatology (Member)

Philadelphia Dermatological Society (Member)

Philadelphia College of Physicians (Fellow)

Committees in National Organizations:

Cutaneous Lymphoma Foundation

2011-2013
President, Executive Committee
2002-2011
Chairman, Medical Advisory Board
1998
Founding Director

Dermatology Foundation

2013
Vice-President, Executive Committee
2009-2012
Secretary/Treasurer, Executive Committee
2005
Chair, Leaders Society Committee
2003-2004
Vice-Chair, Leaders Society Committee
2002-2003
Leaders Society Committee
1995-2005
Chair, Pennsylvania Leaders Society Campaign
1993-1995
Vice-Chair, Pennsylvania Leaders Society Campaign

United States Cutaneous Lymphoma Consortium

2010-2013
Chair, Programs Committee

American Academy of Dermatology

2010-2014
Grassroots Advocacy Committee
2005-2008
Patient Advocate Task Force
1999-2000
Program for Dermatology for the 21st Century: Skin Cancer

Society for Investigative Dermatology

2004-2009
Committee on Finances
1999-2003
Committee on Long-Range Planning and Priorities

National Comprehensive Cancer Network

2002-2006
Non-melanoma Skin Cancer Committee

Philadelphia Dermatological Society

2004
Executive Committee
2004-2005
President, Executive Committee
1995-1997
Executive Committee

Editorial Positions:

2010
Reviewer, New England Journal of Medicine
2010
Reviewer, Clinical and Experimental Dermatology
2009
Reviewer, Cancer Prevention Research
2008
Reviewer, American Journal of Pathology
2006
Reviewer, American Journal of Preventive Medicine
2002
Reviewer, Molecular Carcinogenesis
2001
Reviewer, British Journal of Dermatology
1999
Reviewer, Blood
1998
Reviewer, Molecular Diagnostics
1996
Reviewer, Journal of Cutaneous Pathology
1995
Reviewer, Cancer Research
1995
Reviewer, Journal Clinical Allergy & Immunology
1992
Reviewer, Journal of Investigative Dermatology
1992
Reviewer, Archives of Dermatology
1992
Reviewer, Journal of the American Academy of Dermatology

Principal Investigator of Grants / Clinical Trials:

PAST
Pathogenesis of Human T-cell Leukemias/Lymphomas
NIH K11 AM01645
$364,750
7/1986-6/1991

Molecular Diagnosis of Cutaneous T-cell Lymphoma
Lester I Conrad Foundation
$10,000
12/1990-11/1091

Molecular Diagnosis of Cutaneous T-cell Lymphoma
Dermatology Foundation
$120,000 – relinquished due to budgetary overlap
7/1991-6/1994

Molecular Characterization of Cutaneous T cell Lymphoma
9/1991-8/1996
NIH R29 CA55017
$349,998

Molecular Characterization of Cutaneous T cell Lymphoma
VA Merit Review
$227,500 – relinquished due to budgetary overlap
4/1991-3/1994

Molecular Characterization of Cutaneous T cell Lymphoma
VA RA1710
$269,000
4/1991-3/1996

Patient-Oriented Research in Cutaneous Oncology
NIH K24 AR02102
$437,500
7/1999-6/2004

Phase II Trial Testing Safety & Efficacy of Bexarotene 1% Gel in Parapsoriasis
Ligand Pharmaceutics, Inc., San Diego, CA.
$50,000
4/2001-3/2004

Melanoma Family Risk Assessment Program Registry & Tissue Bank
Dermatology Foundation
$10,000
7/2002-6/2003

Biomarkers of Genetic Susceptibility to Melanoma
Cancer Research Foundation of America
$80,000
1/2002-12/2003

Biomarkers of Biomarkers of Genetic Susceptibility to Melanoma
Skin Cancer Foundation of America
$10,000
3/2002-2/2003

Melanocyte DNA Repair Capacity and Melanoma Susceptibility
Mary L. Smith Charitable Lead Trust
$65,010
7/2002- 6/2003

Topical Nitrogen Mustard Treatment of Mycosis Fungoides (IND 67,839/NCT00168064)
FDA R01 FD003017
$1, 276,602
3/2006-8/2010

Patents:

USPTO 13786392:
Apparatus for Reconstituting & Dispensing Drugs for Topical Application

Study Section Positions:

1993-1997
Dermatology Foundation Medical-Scientific Committee (Member)
2001
FDA Orphan Product Development Program (Ad hoc Reviewer)

National & International Meetings & Sessions Chaired

Sept. 30, 1999
Chairman, Inaugural Wallace H. Clark, Jr., M.D. Lectureship in Cutaneous Oncology & Melanoma Symposium, Philadelphia, Pa.
May 1, 2003
Co-Chair, CTCL Satellite Symposium, International Investigative Dermatology 2003 Meeting, Miami Beach, FL.
Apr. 30, 2004
Co-Chair, CTCL Symposium, 65th Meeting of the Society for Investigative Dermatology, Providence, RI.
May 5, 2005
Co-Chair, CTCL Symposium, 66th Meeting of the Society for Investigative Dermatology, St. Louis, MO.
May 4, 2006
Co-Chair, CTCL Symposium, 67th Meeting of the Society for Investigative Dermatology, Philadelphia, PA.
May 4-6, 2007
Chairman, 84th Atlantic Dermatologic Conference, Philadelphia, PA.
May 10, 2007
Co-Chair, CTCL Symposium, 68th Meeting of the Society for Investigative Dermatology, Los Angeles, CA.
Oct. 5, 2007
Co-Chair, Adverse Drug Reactions — Pharmacology & Drug Therapy Session, 21st World Congress of Dermatology, Buenos Aires, Argentina
Jan. 29-31, 2009
Co-Chair, Dermatology Foundation Clinical Symposia, Naples, FL.
Oct. 9-11, 2009
Co-Chair, Cutaneous Lymphoma Summit 2009, New York, NY
Jan 21-23, 2010
Co-Chair, Dermatology Foundation Clinical Symposia, Naples, FL.
May 6, 2010
Co-Chair, CTCL Symposium, 70th Meeting of the Society for Investigative Dermatology, Atlanta, GA.
May 8, 2010
Co-Chair, Clinical Research and Therapeutics Symposium, 70th Meeting of the Society for Investigative Dermatology, Atlanta, GA.
Sept. 22, 2010
Co-Chair, Practical Issues in the Management of Patients with Cutaneous Lymphoma Workshop, First World Congress for Cutaneous Lymphomas, Chicago, IL.
Sept. 24, 2010
Co-Chair, Response Criteria/Endpoints & Skin-Directed Therapies Session, First World Congress for Cutaneous Lymphomas, Chicago, IL.

Lectures by Invitation:

9-22-10
“Use & Abuse of Topical Steroids in CTCL”. First World Congress for Cutaneous Lymphomas, Chicago, IL.
4-13-10
“Mycosis Fungoides and Related Disorders” Delaware Dermatology Society, Newark, Delaware
05-02-09
“Epidemiology of Mycosis Fungoides”. 12th World Congress on Cancers of the Skin, Tel Aviv, Israel
01-29-09
“Office Management of T-cell Lymphoproliferative Diseases”. Dermatology Foundation Clinical Symposia, Naples, Fl.
03-13-08
“Alibert's Lymphoma: Mycosis Fungoides at 202”. Visiting Professor, Duke University, Durham,
05-30-07
“Alibert's Lymphoma: Mycosis Fungoides at 200”. Tel Aviv University-Rabin Medical Center. Petah Tikva, Israel
11-17-06
“Clinical Endpoints in CTCL: Response Duration & Relapse”. Duke Clinical Research Institute Think Tank on CTCL Clinical Responses and Endpoints. Washington, D.C.
03-08-06
“Chemotherapy Induced Cutaneous Inflammation”. Brendan Society Biennial Meeting, Carmel, Ca.
10-21-05
“Cutaneous T-Cell Lymphoma & Lymphoproliferative Disorders of the Skin”. Young Leaders in Dermatology Symposium. Tucson, AZ.
04-30-04
“CTCL Immunobiology and Pathogenesis”. CTCL Symposium, Society for Investigative Dermatology Annual meeting, Providence, RI.
10-17-03
"Melanoma & Non-Melanoma Skin Cancer". Stuart Katz Memorial Lecture, Lankenau Hospital, Wynnewood, PA.
10-1-03
"Skin Cancer". 27th Semi-Annual Fall Family Practice Review Program, Lancaster, PA.
2-21-03
"What's Next for Rexinoids: Novel Approaches to T-Cell Mediated Diseases". 27th Annual Hawaii Dermatology Seminar, Maui, HI.
1-23-03
"Reducing Morbidity & Mortality in Cutaneous T-Cell Lymphoma " Mt. Sinai Medical Center, New York, NY.
4-26-02
"Melanoma Prevention: Developing New Risk Assessment Tools" Visiting Professor, Geisinger Medical Center, Danville, Pa.
4-10-02
"Recognizing Skin Cancer: What you need to know" American College of Physicians Annual Session, Philadelphia, Pa.
10-15-00
"Chemoprevention in Cutaneous T-Cell Lymphoma" St. Lukes-Roosevelt Medical Center, New York, NY.
9-24-00
"Therapeutic TCR-Vβ DNA Vaccines in Cutaneous T-Cell Lymphoma" Basic and Clinically Relevant Biology in Cutaneous T-Cell Lymphoma- New York Academy of Sciences Conference, New York, NY
9-17-00
"Prevention Strategies for Cutaneous T-Cell Lymphoma" Hugh Crumay Pennsylvania Professor, Pennsylvania Academy of Dermatology Annual Meeting, Hershey, Pa.
5-12-99
"Targeting Tumor Associated Antigens in Cutaneous T-Cell Lymphoma” Visiting Professor, Yale University Medical Center, New Haven, Ct.
12-17-98
"Mycosis Fungoides & Sezary Syndrome: Rational Approach to Therapy " Visiting Professor, Emory University Medical Center, Atlanta, Ga.
12-10-98
"Mycosis Fungoides: 200 Years Later " Visiting Professor, Brown University, Rhode Island Hospital, Providence, RI.
2-28-98
"DNA Vaccination" American Academy of Dermatology Annual Meeting, Orlando, Fl.
2-26-98
"The Role of Gene Rearrangement Studies in the Evaluation of Lymphoproliferative Skin Diseases" International Society of Dermatopathology Joint Meeting, Orlando, Fl.
2-18-98
"T-Cell Receptor Targeting in Inflammatory & Neoplastic Skin Diseases" The Immune Response Corporation, Carlsbad, Ca.
11-18-97
"T-Cell Receptor DNA Vaccination in Cutaneous T-Cell Lymphoma" IBC 3rd Annual Genetic Vaccines & Immunotherapeutic Strategies Conference, Orlando, Fl.
11-12-97
"DNA Vaccination and Skin" Dermatology 2000 - University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical Center, New Brunswick, NJ.
3-23-97
"T-Cell Receptor Expression in Inflammatory & Neoplastic Skin Diseases”. American Academy of Dermatology Annual Meeting, San Francisco, Ca.
12-17-96
"Parapsoriasis Revisited" Visiting Professor, Cornell Medical Center, New York, NY
10-31-96
"Parapsoriasis at 100: New Clinical Challenges" Utah Parapsoriasis Workshop, University of Utah, Salt Lake City, UT.
02-13-96
"Molecular Biology and Retrovirology of Cutaneous T-Cell Lymphoma" American Academy of Dermatology Annual Meeting, Washington, D.C.
02-07-95
"Diagnostic Utility of Molecular Studies in Cutaneous T-Cell Lymphoma" American Academy of Dermatology Annual Meeting, New Orleans, LA.
12-15-94
"Molecular Diagnosis of Parapsoriasis and Cutaneous T-Cell Lymphoma" State University of New York, Stony Brook, NY
10-11-94
"Parapsoriasis Update: Differentiation from Mycosis Fungoides" Dermatologic Society of New Jersey, Union, NJ.
3-18-94
"Cutaneous T-Cell Lymphoma as a Model of Tumor Progression" Howard Fox Visiting Professor, NYU, New York, NY.
6-15-92
"Molecular Diagnosis and Immunomodulatory Therapy in CTCL" 18th World Congress of Dermatology, NYC, NY.
1-29-92
"Clonal Evolution of Cutaneous T-Cell Lymphoma" Columbia University, NYC, NY.
4-22-91
"Molecular Diagnosis of Cutaneous T-Cell Lymphoma: New Insights into Biology and Treatment" Visiting Professor, Boston/Tufts/Harvard University, Boston, MA.
11-29-90
"Deciphering Clonality and Gene Rearrangements" American Society of Dermatopathology Annual Meeting, Atlanta, GA.
6-17-90
"Immunogenotyping Cutaneous T-Cell Lymphoma" American Academy of Dermatology Annual Meeting, Boston, MA.
11-21-89
"Molecular Characterization of Cutaneous T-Cell Lymphoma" Dermatology Grand Rounds, NCI-NIH, Bethesda, MD.

Bibliography:

Original Papers:

  1. Nicolini, C., Belmont A., Parodi, S., Lessin, S.R., and Abraham, S. 1979. Mass action and acridine orange staining: Static and flow microfluorimetry. J. Histochem. Cytochem. 27:102-113.
  2. Parodi, S., Beltrame, F., Lessin, S.R., and Nicolini, C. 1979. Morphometric analysis of B2cAMP-induced reverse transformation in synchronized CHO cells. Cell Biophys. 1:271-292.
  3. Grattarola, M., Zietz, S., Lessin S.R., Desaive, C., and Nicolini, C. 1979. Early detection of micrometastases via flow microfluorimetry. Cancer Biochem. Biophys. 4:13-18.
  4. Zietz, S., Lessin, S.R., Grattarola, M., Desaive, C., and Nicolini, C. 1980. FPi analysis II: Use of the method to monitor the in vivo kinetics of cell populations perturbed by hydroxyurea. Cell Tissue Kinetics 13:473-484.
  5. Lessin, S.R., Abraham, S., and Nicolini, C. 1982. Biophysical characterization and sorting of high metastatic variants from B16 melanoma tumor. Cytometry 2:407-413.
  6. Jensen, P., Baird, J., Morioka, S., Lessin, S.R., and Lazarus, G. 1988. Epidermal plasminogen activator is abnormal in cutaneous lesions. J. Invest. Dermatol. 90:777-782.
  7. Lessin, S.R., Grove, G., Diamond, L., Au, F., Nowell, P.C., and Vonderheid, E. 1988. DNA-cytophotometry of lymph node touch imprints in cutaneous T-cell lymphoma. J. Invest. Dermatol. 90:425-429.
  8. Lessin, S.R., Huebner, K., Isobe, M., Croce, C.M., and Steinert, P. 1988. Chromosomal mapping of human keratin genes: Evidence of non-linkage. J. Invest. Dermatol. 91:572-578.
  9. McKinley-Grant, L.J., Idler, W., Bernstein, I.A., Parry, D., Cannizzaro, L., Croce, C.M., Huebner, K., Lessin, S.R., and Steinert, P. 1989. Characterization of a cDNA encoding human filaggrin and localization of the gene to chromosome region 1q21. Proc. Natl. Acad. Sci. USA 86:4848-4852. 9a. Nordstrom KM, McGinley KJ, Lessin SR, Leyden JJ. 1989. Neutral lipid composition of Fordyce's granules. Br J Dermatol. 121:669-670.
  10. Kozbor, D., Cassatella, M., Lessin, S., Kagan, J., Finver, S., Faust, J., Trinchieri, G., and Croce, C.M. 1990. Expression and function of ∂γ and αβ-T cell receptor heterodimers on human somatic T cell hybrids. J. Immunol. 144:3677-3683.
  11. Jaworsky, C., Cirrillo-Hyland, V., Petrozzi, J., Lessin, S., Murphy, G. 1990. Regressing atypical histiocytosis: Aberrant prothymocyte differentiation, T-cell rearrangements and nodal involvement Arch. Dermatol.126:1609-1616.
  12. Abrams, J.T., Lessin, S.R., Ghosh, S., Ju, W., Vonderheid, E., Nowell, P.C., Murphy, G., Elfenbein, and DeFreitas, E. 1991. A clonal CD4 positive cell line established from the blood of a patient with Sezary syndrome. J. Invest. Dermatol.96: 31-37.
  13. Lessin, S.R., Rook, A.H. and Rovera, G. 1991. Molecular diagnosis of cutaneous T-cell lymphoma: Polymerase chain reaction amplification of T-cell antigen receptor β-chain gene rearrangements. J. Invest. Dermatol. 96(3): 299-302.
  14. Abrams, J.T., Lessin, S.R., Ghosh, S., Ju, W., Nowell, P.C., Vonderheid, E., Rook, A.H. and DeFreitas, E. 1991. Malignant and non-malignant T-cell lines from HTLV-I negative patients with Sezary syndrome. J. Immunol. 146(5): 1455-1462.
  15. Rook, A.H., Prystowsky, M.B., Cassin, M., Boufal, M., Lessin, S.R. 1991. Combined therapy of the Sezary syndrome with extracorporeal photochemotherapy and low dose interferon-α: clinical, molecular and immunologic observations. Arch. Dermatol. 127:1535-1540.
  16. Cohen, J.H., Lessin, S.R., Vowels, B.R., Benoit. B., Witmer, W.K. and Rook, A.H. 1993. The sign of Leser-Trelat in association with Sezary Syndrome: Simultaneous disappearance of seborrheic keratoses and malignant T-cell clone during combined therapy with photopheresis and interferon-alpha. Arch. Dermatol. 129: 1213-1214.
  17. Schechter, N.M., Wang, Z.M., Blacher, R.W., Lessin, S.R., Lazarus, G.S. and Rubin, H. 1994. Determination of the primary structures of human skin chymase and cathepsin G from cutaneous mast cells of urticaria pigmentosa lesions. J. Immunol. 152: 4062-4069.
  18. Vowels, B.R., Lessin, S.R., Cassin, M., Jaworsky, C., Benoit, B., Wolfe, J.T. and Rook, A.H. 1994. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J. Invest. Dermatol. 103: 669-673.
  19. Rook, A.H. Kubin, M., Cassin, M., Vonderheid, E. C., Vowels, B.R., Wolfe, J.T., Wolf, S.F., Singh, A., Trinchieri, G. and Lessin, S.R. 1995. Interleukin 12 reverses cytokine and immune abnormalities in Sezary syndrome. J. Immunol. 154: 1491-1498.
  20. Wolfe, J.T., Chooback, L., Finn, D.T., Benoit, B.M., Jaworsky, C., Rook, A.H. and Lessin, S.R. 1995. Large cell transformation following detection of minimal residual disease in cutaneous T-cell lymphoma: Molecular and in-situ analysis of a single T-cell clone expressing the identical T-cell receptor. J. Clin. Oncol. 13:1751-1757.
  21. Wolfe, J.T., Singh, A, Lessin, S.R. and Rook, A.H. 1995. De-novo development of psoriasis in patients receiving interferon-alfa for erythrodermic cutaneous T-cell lymphoma: A report of two cases and review of the literature. J. Am. Acad. Dermatol. 32: 887-993.
  22. Resnick, K.S., Kantor, G.R., Lessin, S.R., Kadin, M.E., Chooback, L., Cooper, H.S. and Vonderheid, E.C. 1995. Mycosis fungoides palmaris et plantaris. Arch. Dermatol. 131: 1052-1056.
  23. Peluso, A.M., Bonifas, J.M., Ikeda, S., Hu, Z., Devries, S., Waldman, F., Badura, M., O'Connell, P., Damen, L., Epstein, E., Franzblau, M., Herman, P., Lessin, S.R., Swerlick, R., Trask, D. and Epstein, E.I. 1995. Narrowing of the Hailey-Hailey disease gene region on chromosome 3q and identification of one kindred with a deletion in this region. Genomics 30: 77-80.
  24. Weinberg, J.M., Jaworsky, C., Benoit, B.M., Telegan, B., Rook, A.H. and Lessin, S.R. 1995. The clonal nature of circulating Sezary cells. - Blood 86: 4257-4262.
  25. Wasik, M.A., Vonderheid, E.C., Bigler, R.D., Marti, R., Lessin, S.R., Polansky, M. and Kadin, M.E. 1996. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma: clinical and prognostic implications. - Arch. Dermatol. 132: 42-47.
  26. Kang, K., Kubin, M., Cooper, K.D., Lessin, S.R., Trinchieri, G. and Rook, A.H. 1996. IL-12 synthesis by human Langerhans cells. J. Immunol. 156: 1402-1407.
  27. Vonderheid, E.C., Zhang, Q., Wasik, M.A., Lessin, S.R., Polansky, M., Abrams, J.T. and Bigler, R.D. 1996. Use of serum soluble interleukin-2 receptor levels to moniter extracorporeal photopheresis in cutaneous T cell lymphoma. - Arch. Dermatol. 132: 42-47.
  28. Finn, D.T., Jaworsky, C., Chooback, L., Jensen, P.J. and Lessin, S.R. 1996. Correlation between clonotypic T-cell receptor beta chain variable region gene expression and aberrant T-cell antigen expression in cutaneous T-cell lymphoma. J. Cutaneous Pathol. 23: 306-311.
  29. Dietz, S.B., Whitacker-Menezes, D. and Lessin, S.R. 1996. The role of αEβ7 integrin (CD103) and E-cadherin in epidermotropism in cutaneous T-cell lymphoma. J. Cutaneous Pathol. 23: 312-318.
  30. Li, G., Vowels, B.R., Benoit, B., Rook, A.H. and Lessin, S.R. 1996. Failure to detect human T-lymphotropic virus type-I (HTLV-I) proviral DNA in cell lines and tissues in patients with cutaneous T-cell lymphoma. - J. Invest. Dermatol. 107: 308-313.
  31. Gottlieb, S., Wolfe, J., Fox, F., Denardo, B., Macey, W., Bromley, P, Lessin, S.R. and Rook, A. 1996. Treatment of cutaneous T-cell lymphoma with extracoporeal photochemotherapy monotherapy and in combination with recombinant interferon alfa: A 10-year experience at a single institution. J Am Acad Dermatol. 35:946-457.
  32. Gilliam, A.C., Lessin, S.R. and Salhany, K.E. 1997. Folliculotropic mycosis fungoides with large cell transformation presenting as dissecting cellulitis. J. Cutaneous Pathol. 24:169-75.
  33. Li, G., Salhany, K.E., Rook, A.H. and Lessin, S.R. 1997. The pathogenesis of large cell transformation in cutaneous T-cell lymphoma is not associated with t(2;5)(p23;q35) chromasomal translocation. J. Cutaneous Pathol. 24:403-408.
  34. Vonderheid, E.C., Zhang, Q., Lessin, S.R., Poalansky, M. Abrams, J.T., Bigler, R.D. and Wasik, M.A. 1998. Use of serum soluable interleukin-2 receptor levels to monitor progression of T-cell lymphoma. J. Am. Acad. Dermatol. 38:207-220.
  35. Li, G, Chooback, L., Wolfe, J.T., Rook, A.H., Felix, C.A., Lessin, S.R. and Salhany, K.E. 1998. Overexpression of p53 protein in cutaneous T-cell lymphoma: relationship to large cell transformation and disease progression. J. Invest. Dermatol. 110: 767-770.
  36. Salhany, K.E., Macon, W.R., Choi, J.K., Elenitsas, R., Lessin, S.R., Felgar, R.E., Wilson, D.M., Przybylski, G.K., Lister, J., Wasik, M.A. and Swerdlow, S.H. 1998. Subcutaneous panniculitis T-cell lymphoma: clinicopathologic, immunophenotypic and genotypic analysis of αβ and ∂γ subtypes. Am . J. Surg. Pathol. 22: 881-893.
  37. Micaily, B., Miyamoto, C., Kantor, G., Lessin, S.R., Rook, A.H., Brady, L., Goodman, R. and Vonderheid, E.C. 1998. Radiotherapy for unilesional mycosis fungoides. Int. J. Rad. Oncol. Biol. Physics 42:361-364.
  38. Chan E, Thakur A, Farid L, Lessin S, Uberti-Benz M, James W. 1998. Pemphigus vulgaris of the cervix and upper vaginal vault: a cause of atypical papanicolaou smears. Arch Dermatol. 134:1485-1486.
  39. Lessin, S.R., Benoit, B., Li, G., Moskovitz, A. and Zweiman, B. 1999. Quantitative analysis of T-cell receptor ß variable gene (TCR-Vß) usage in cutaneous late phase reactions: implications for T-lymphocyte recruitment in cutaneous inflammation. Clin. Diagnostic Lab. Immunol. 6:85-88.
  40. Zhang, Q., Lee, B., Korecka, M., Li, G., Weyland, C., Eck, S., Gessain, A., Arima, N., Shaw, L., Luger, S., Kamoun, M., Wasik, M.A. 1999. Differences in phosphorylation of the IL-2R associated Jak/STAT proteins between HTLV-I(+), IL-2 independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia (ATLL). Leukemia Research 23:373-384.
  41. Rook, A.H., Wood, G.S., Yoo, E.K., Elenitsas, R., Kao, D.M.F., Sherman, M.L., Witmer, W.K., Rockwell, K.A., Shane, R.B., Lessin, S.R., Vonderheid, E.C. 1999. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94:902-908.
  42. Wu, H., Telang, G., Lessin, S.R., Vonderheid, E.C. 2000. Mycosis Fungoides with CD-30 positive cells in the epidermis. Am. J. Dermatopathol. 22:212-216.
  43. Zweiman B, Parrott CM, Graif Y, David M, Lessin SR. 2000. Quantitative comparison of cytokine mRNA and inflammatory responses in cutaneous late phase allergic reactions. Cytokine 12: 1065-1075.
  44. Gregg, P.J., Kantor, G.R., Telang, G., Lessin, S.R., Nowell, P.C., Vonderheid, E.C. 2000. Sarcoidal tissue reaction in Sezary syndrome. J Am Acad Dermatol. 43:372-376.
  45. Galindo LM, Garcia FU, Hanau CA, Lessin SR, Jhala N, Bigler RD, Vonderheid EC. 2000. Fine-needle aspiration biopsy in the evaluation of lymphadenopathy associated with cutaneous T-cell lymphoma (mycosis fungoides/Sezary syndrome). Am J Clin Pathol 113:865-871.
  46. Egan CL, Liu V, Harris RM, White SM, Lessin SR, Weinberg JM. 2000. Linear IgA disease associated with membranous glomerulonephropathy. Int J Dermatol 39:379-382.
  47. Wildemore JK 4th, Schuchter L, Mick R, Synnestvedt M, Elenitsas R, Bedrosian I, Czerniecki BJ, Guerry D 4th, Lessin SR, Elder DE, Bucky LP. 2001. Locally recurrent malignant melanoma: characteristics and outcomes - a single institution study. Ann Plast Surg.46:488-494.
  48. Yoo E.K., Cassin M., Lessin S.R., Rook, A.H. 2001. Complete molecular remission during biologic response modifier therapy for Sezary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. J. Am. Acad. Dermatol. 45: 208-216.
  49. Luo V, Lessin SR, Wilson RB, Rennert H, Tozer C, Benoit B, Leonard DG. 2001. Detection of clonal T-cell receptor gamma gene rearrangements using fluorescent-based PCR and automated high-resolution capillary electrophoresis. Mol Diagn. 6:169-79.
  50. French, L.E., Lessin, S.R., Addya K., Denardo, B., Margolis, D.J., Leonard, D.G.B., Rook, A.H. 2001. Identification of Clonal T Cells in the Blood of Patients with Systemic Sclerosis: Positive Correlation with Response to Photopheresis. Arch Dermatol 137:1309-1313.
  51. Vonderheid EC, Bigler RD, Kotecha A, Boselli CM, Lessin SR, Bernengo MG, Polansky M. 2001. Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sezary syndrome). J Invest Dermatol. 117:654-662.
  52. Berking C, Takemoto R, Binder R, Ruiter D, Lessin SR, Herlyn M. 2002. Photocarcinogensis in human adult skin grafts. Carcinogenesis 23:181-187.
  53. McGinnis KS, Lessin, SR, Elder DE, Guerry D, Schuchter L, Ming, M, Elenitsas R. 2002. Pathology review of melanoma cases presenting to a multidisciplinary pigmented lesion clinic. Arch Dermatol 138: 617-621.
  54. Weinberg JM, Kristal L, Chooback L, Honig P, Kramer EM, Lessin SR. 2002. The clonal nature of pityriasis lichenoides. Arch Dermatol 138:1063-7.
  55. McGinnis K, Shapiro M, Junkins-Hopkins JM, Smith M, Lessin SR, Vittorio, C, Rook AH. 2002. Denileukin Diftitox (Ontak®) for the treatment of panniculitic lymphoma. Arch Dermatol 138:740-2.
  56. Wu H, Smith M, Millenson MM, Nicolaou N, Van Deerlin V, Addya K, Lessin SR, Al Saleem TI. 2003. Contribution of flow cytometry to the diagnosis of cutaneous lymphoid lesions. J Invest Dermatol 121:1522-1530.
  57. Edwards, RH, Ward MR, Wu H, Medina A, Brise MS, Volpe P, Nussen-Less S, Haupt HM, Martin A-M, Herlyn M, Lessin SR, Weber, B. 2004. Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genetics 41:270-2.
  58. T J Mueller, H Wu, RE Greenberg, G Hudes, N Topham, SR Lessin, RG Uzzo. 2004. Cuataneous metastases from genitourinary malignancies. Urology 63:1021-6.
  59. Manne, S., Fasanella, N, Connors, J., Floyd, B., SR Lessin , S. 2004. Sun protection and skin surveillance practices among relatives of patients with malignant melanoma: Prevalence and Predictors. Preventive Medicine 39:36-47.
  60. Dorgan JF, Boakye NA, Fears TR, Schleicher RL, Anderson C, Helsel W, Lessin SR, Ratnasinghe LD, Tangrea JA. 2004. Serum Carotenoids and α-tocopherol and risk of non-melanoma skin cancer. Cancer Epidemiology, Biomarkers and Prevention 13:1276-82.
  61. Wu H, Barusevicius A, Lessin SR. 2004. Granuloma annulare with a mycosis fungoides-like distribution – J Am Acad Dermatol 51:39-44.
  62. Wu H, Barusevicius A, Babb J, Klein-Szanto A, Godwin A, Elenitsas R, Gelfand JM, Lessin S, Seykora JT. 2005. Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential. J Cutan Pathol. 32:125-30.
  63. Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, Burg G,…Lessin S, Wood GS. 2005. Defining early mycosis fungoides. J Am Acad Dermatol. 53:1053-63.
  64. Nebozhyn M, Loboda A, Kari L, Rook AH, Vonderheid EC, Lessin S, Nichols C, Yousef M, Gudipathi L, Showe MK Showe LC. 2006. Quantitative PCR on 5 Genes Identifies CTCL Patients With 5-95% Circulating Tumor Cells with 90% Accuracy. Blood. 107: 3189-3196.
  65. Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR. 2006. Cutaneous B cell lymphoma responds to rituximab: A report of five cases and review of the literature. Leukemia & Lymphoma. 47(9):1902-1907.
  66. Manne S, Lessin S. 2006. Prevalence and correlates of sun protection and skin self-examination practices among cutaneous malignant melanoma survivors. J Behavioral Med 29(5):419-34.
  67. Miller SJ, Alam M, Andersen J, Berg D, Bichakjian CK, Bowen G, Cheney RT, Glass F, Grekin RC, Grichnik JM, Johnson TM, Kessinger A, Lee NY, Lessin S, Lydiatt DD, Margolis LW, Nehal KS, Nghiem P, Oseroff AR, Rosenberg EW, Shaha AR, Siegle RJ; National Comprehensive Cancer Network. 2006. Merkel cell carcinoma. J Natl Compr Canc Netw. 4(7):704-12.
  68. Sariya D, Ruth K, Adams-Mcdonnell R, Cusack C, Xu X, Elenitsas R, Seykora J, Pasha T, Zhang P, Baldassano M, Lessin SR, Wu H. 2007. Clinicopathologic correlation of cutaneous metastases: experience from a cancer center. Arch Dermatol. 143:613-620.
  69. Singh MK, Nicolas E, Gherraby W, Dadke D, Lessin S, Golemis EA. 2007. HEI-10 negatively regulates cell motility by inhibiting cyclin B/Cdk1. Oncogene 26(33):4825-32
  70. Shafer D, Wu H, Al-Saleem T, Reddy K, Borghaei H, Lessin S, Smith M. 2008. Cutaneous precursor B-cell lymphoblastic lymphoma in 2 adult patients: clinicopathologic and molecular cytogenetic studies with a review of the literature. Arch Dermatol.144(9):1155-62. PMID: 18794461
  71. Lessin SR, Ross EA, Wu H. 2008. Treatment of parapsoriasis with bexarotene 1% gel. International J Dermatol. 47: 1325-1327. PMID: 19126035
  72. Xu X-Z, Garcia MV, Li T-Y, Khor L-Y, Gajapathy RS, Spittle CA, Weed S, Lessin SR, Wu H. 2010. Cytoskeleton alterations in melanoma: Aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression. Modern Pathology 23:187-96. PMID: 19898426
  73. Manne S, Jacobsen PB, Ming ME, Winkel G, Dessureault S, Lessin SR. 2010. Tailored Versus Generic Interventions for Skin Cancer Risk Reduction for Family Members of Melanoma Patients. Health Psychology. 29(6): 583-593. PMID: 21090893
  74. Manne SL, Coups EJ, Jacobsen PB, Ming M, Heckman CJ, Lessin SR. 2011. Sun Protection and Sunbathing Practices Among At-Risk Family Members of Patients with Melanoma. BMC Public Health 11:122. PMID: 21338483
  75. Olsen EA, Whittaker S, Kim Y, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre M-F, Pimpinelli N, Grazia Bernengo M, Ortiz Romero P, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Laroche L, Horwitz S, Rosen S, Cerroni L, Dreno B, Vonderheid EC. 2011. Clinical Endpoints and Response Criteria in Mycosis Fungoides and Sézary Syndrome: a Consensus Statement of the International Society for Cutaneous Lymphomas (ISCL), the United States Consortium for Cutaneous Lymphomas (USCCL) and the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer (EORTC). J Clin Oncol 29(18):2598-607. PMID: 21576639
  76. Coups EJ, Manne SL, Jacobsen PB, Ming ME, Heckman CJ, Lessin SR. 2011. Skin surveillance intentions among family members of patients with melanoma. BMC Public Health 11:866. PMID: 22082038
  77. Heckman CJ, Manne SL, Kloss JD, Bass SB, Collins B, Lessin SR. 2011. Beliefs and intentions for skin protection and exposure. American Journal of Health Behavior. Am J Health Behav. 35(6):699-711. PMID: 22251761
  78. Boris C, Lessin SR, Wintrroub, Yancey KB. 2012. A retrospective analysis of the Dermatology Foundation's career development award program. J Am Acad Dermatol. 67(5):969-74. doi: 10.1016/j.jaad.2012.02.032. Epub 2012 Mar 28. PMID: 22459361
  79. Lessin SR, Duvic M, Guitart J, Pandya A, Strober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH. 2013. Topical Chemotherapy in Cutaneous T-cell Lymphoma: Positive Results of a Randomized, Controlled, Multi-center Trial Testing the Efficacy and Safety of a Novel 0.02% Mechlorethamine Gel in Mycosis Fungoides. JAMA Dermatol. 149(1):25-32. doi: 10.1001/2013.jamadermatol.541. PMID: 23069814
  80. Hodak E, Lessin S, Friedland R, Freud T, David M, Pavlovsky L, Shapiro J, Cohen AD. 2013. New Insights into Associated Co-morbidities in Patients with Cutaneous T-Cell Lymphoma (Mycosis Fungoides). Acta Derm Venereol. doi: 10.2340/00015555-1496. [Epub ahead of print] PMID: 23303582

Text Books (Electronic):

  1. Heymann WR, Anderson B, Hivnor D, Lessin S (editors) Clinical Decision Support: Dermatology, Decision Support in Medicine, LLC, Wilmington. September 2012.

Chapters, Reviews, Editorials & Letters to the Editor:

  1. Nicolini, C., Parodi, S., Lessin, S.R., Belmont, A., Abraham, S., Zietz, S., and Grattarola, M. 1979. Chromatin study in situ. II. Static and flow microfluorimetry. In: Chromatin Structure and Function (C. Nicolini, ed.). Plenum Press, NY, pp. 293-322.
  2. Parodi, S., Brombilla, G., Beltrame, F., Lessin, S.R., and Nicolini, C. 1979. Cellular morphometry in transformation, differentiation and aging. In: Chromatin Structure and Function (C. Nicolini, ed.). Plenum Press, NY, pp. 721-750.
  3. Nicolini, C., Beltrame, F., Lessin, S.R., and Parodi, S. 1979. Analytical cytology as a screening method for chemical carcinogens. In: Short-Term Tests for Prescreening of Carcinogens (L. Santi and S. Parodi, eds). Instituto Scientifico per lo Studio e la Cura dei Tumori, Genova, Italy, pp. 151-167.
  4. Nicolini, C., Lessin, S.R., Abraham, A., Zietz, C., and Chiabrera, S. 1982. Growth parameters in normal and tumor cells: Non-cycling and metastatic variants, as monitored by flow cytometry. In: Cell Growth (C. Nicolini, ed.). Plenum Press, NY, pp. 133-170.
  5. Rook, A., Nahaas, G., Macelis, B., Macey, W., and Lessin, S.R. 1989. Extracorporeal photochemotherapy in the treatment of cutaneous T-cell lymphoma and autoimmune disorders affecting the skin. In: Photosensitizing Compounds: Their Chemistry, Biology and Clinical Use (S. Harnett, ed.). CIBA Foundation Symposium, Ardsely, NY, pp. 171-182.
  6. Abrams, J.T., Lessin, S., Ju, W., Vonderheid, E., Rook, A., Nowell,. P., Kadin, M. and DeFreitas, E. 1990. Analysis of T-cells and long-term T-cell lines from patients with Sezary syndrome. In: Human Retrovirology: HTLV (W.A. Blattner, ed.) Raven Press, N.Y., pp. 147-161.
  7. Lessin, S.R. 1991. Topical steroids. In: Dermatology diagnosis and therapy (E. Bondi, B. Jegasothy, and G. Lazarus, ed.). Appleton-Lange Publications, San Mateo, CA, pp. 343-346.
  8. Rook, A.H., Cohen, J.H., Lessin, S.R. and Vowels, B.R. 1993 Therapeutic applications of photopheresis. In: Dermatologic Clinics (B.H. Theirs, ed.). W.B. Saunders, Philadelphia, pp.339-347.
  9. Rook, A.H., Vowels, B.R., Jaworsky, C., Singh, A. and Lessin, S.R. 1993. The immunopathogenesis of cutaneous T-cell lymphoma: Abnormal cytokine production by Sezary T-cells. Arch. Dermatol. 129: 486-488
  10. Lessin, S.R. and Rook, A.H. 1993. Molecular diagnosis and immunomodulatory therapy of cutaneous T-cell lymphoma. In: Dermatology Progress and Prospectives: Proceedings of the 18th World Congress of Dermatology (W.H.C. Burgdorf, S.I. Katz, eds.). Parthenon Publishing, UK. pp.624-625.
  11. Lessin, S.R. and Rook, A.H. 1993. T-cell receptor gene rearrangement studies as a diagnostic tool in lymphoproliferative skin diseases. Exp. Dermatol. 2: 53-62.
  12. Weinberg, J.M., Rook, A.H., Lessin, S.R. 1993. Molecular diagnosis of lymphocytic infiltrates of the skin. Arch. Dermatol. 129: 1491-1499.
  13. Lessin SR. 1993. Dermatology's resident match: it's time for change. Arch Dermatol. 129:1056-1057.
  14. Lessin, S.R., Vowels, B.R. and Rook, A.H. 1994. Retroviruses and cutaneous T-cell lymphoma. .In: Dermatol. Clinics (G. Burg, H. Kerl, B.H. Thiers, eds.). W.B. Saunders, Philadelphia. pp. 243-253.
  15. Vonderheid, E.C., Kantor, G.R., Pequignot, E.C., Lessin, S.R., Nowell, P.C., Elfenbein, I.B., Kerrigan, K. & Kadin, M.E. 1994. Analysis of clinical, histopathologic and immunopathologic parameters in erythrodermic variants of cutaneous T-cell lymphoma with implications for staging. In: Basic Mechanisms of Physiological and Aberrant Lymphoproliferation in the Skin (W.A. van Vloten & W.C. Lambert, eds.). Plenum Press, NY. pp. 275-290.
  16. Wolfe, J.T., Lessin, S.R., Singh, A. and Rook, A.H. 1995. Immunomodulation by photopheresis: Treatment of cutaneous T-cell lymphoma, autoimmune disease and allograft rejection. Artifical Organs. 18: 888-897.
  17. Williams, W.V., Rook, A.H., Freundlich, B.F., Fang, Q., Shaw, E., Lessin, S.R. and Weiner, D.B. 1995. T-cell receptors in scleroderma skin. Proc. NY Acad. Sci. 756: 424-427.
  18. Lessin SR, Vowels BR, Rook AH. 1995. Th2 cytokine profile in cutaneous T-cell lymphoma. [letter] J Invest Dermatol. 105::855-6
  19. Lessin SR, Rook AH, Li G, Wood GS. 1996. HTLV-I and CTCL: the link is missing [letter]. J Invest Dermatol. 107:783-784.
  20. Rook AH, Kubin M, Fox FE, Niu Z, Cassin M, Vowels BR, Gottleib SL, Vonderheid EC, Lessin SR, Trinchieri G. 1996. The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma. Ann N Y Acad Sci. 795:310-318.
  21. Rook, A.H., Gottlieb, S.L., Wolfe, J.T., Vowels, B.R., Rastogi, S.S., Niu, Z., Lessin, S.R. and Fox, F.E. 1997. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Clin. Exp. Immunol. 107 Suppl 1:16-20.
  22. Rook AH, Suchin KR, Kao DM, Yoo EK, Macey WH, DeNardo BJ, Bromely PG, Geng Y, Junkins-Hopkins JM, Lessin SR.. 1999. Photopheresis: Clinical applications and mechanism of action. J. Invest. Dermatol. Symposium Proceedings 4:85-90.
  23. Godillot AP, Fang Q, Higgins T, Pachuk C, Boyer J, Weiner DB, Lessin, SR, Williams WV. 2000. Genetic vaccination targeting T-cell receptors. In: DNA Vaccine: Methods and Protocols (DB Lowrie, ed.). Blackwell Publishing, Oxford, UK.
  24. Lehrer MS, Lessin SR. 2002. Skin cancer. eMedicine.com (SH Plantz, F Talavera, JS Huff, J Adler, J Balentine, eds.). www.eMedicine.com/aaem/topic87.htm
  25. Lessin SR. 2005. Dermatologic diseases. In: NMS Medicine – 5th edition (AR Myers, ed.) Lippincott, Williams & Wilkins, Philadelphia, Pa. pp. 720-768.
  26. Sundermeyer M, Lessin SR, Meropol NJ. 2006. Targeted therapies in colorectal cancer: complications and management. Current Colorectal Cancer Reports 2: 125-134.
  27. Lessin SR. 2006. A new nail in the CTCL coffin [commentary]. J Invest Dermatol. 126(11):2368-9.
  28. Lessin SR. 2007. Cutaneous T-cell lymphoma epidemiology: patients providing the power [editorial]. Arch Dermatol. 143(7):916-8.
  29. O'Neill GM, Seo S, Serebriiskii IG, Lessin SR, Golemis EA. 2007 A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Research. 67(19):8975-9.
  30. Lessin SR. 2009. Alibert lymphoma: renaming mycosis fungoides [comments & opinions]. Arch Dermatol. 145(2): 209-210. PMID: 19221278
  31. Lessin SR, Perlis CS. 2010. Nevus sebaceus. In: Treatment of Skin Diseases, 3rd edition (MG Lebwohl, WR Heymann, J Berth-Jones, I Coulson, eds.), Elsevier Health Sciences, Amsterdam, Netherlands. pp.500-01.
  32. Lessin SR, Porcu P (guest editors). 2010. Proceedings From the Cutaneous Lymphoma Summit 2009. Clinical Lymphoma, Myeloma & Leukemia. Volume 10, Supplement 2. pp. S49-S111.
  33. Lessin SR, Porcu P. 2010. The state of cutaneous lymphomas: a call to action [editorial]. Clinical Lymphoma, Myeloma & Leukemia 10 (Suppl. 2): S55-S58.
  34. Zook MB, Perlis CP, Lessin SR. 2011 Skin cancer and other health effects of indoor tanning. In: Shedding Light on Artificial Tanning (C. Heckman, S. Manne, eds.) Springer Science + Business Media, New York, NY. pp. 95-106.
  35. Lessin SR, Perlis CP, Zook MB, Perlis CP. 2011. How ultraviolet radiation tans skin. In: Shedding Light on Artificial Tanning (C. Heckman, S. Manne, eds.) Springer Science + Business Media, New York, NY. pp. 87-94
  36. Zook MB, Wu H, Lessin SR. 2012. Cutaneous Metastases. In: Dermatology, 3rd edition (J. Bolognia, J. Jorizzo, eds.) Elsevier Health Sciences, Amsterdam, Netherlands. pp. 2049-2055.
  37. Lessin SR. The Cutaneous Lymphoma Foundation: a trusted name in the cutaneous lymphoma community [letter to the editor]. 2012. Clin Dermatol. 30(4):450. PMID: 22682197
  38. Fairley JA, Krueger GG, Lessin SR, Leyden JJ, McBurney EI, Orlow SJ, Tharp MD, Voorhees JJ, Wintroub BU, Yancey KB. 2013. The Dermatology Foundation: partnerships and programs focused on the future. J Invest Dermatol. 2013 Apr;133(4):861-2. doi: 10.1038/jid.2013.15. PMID: 23486423

Abstracts:

  1. Parodi, S, Lessin, S, Fang, S., Zietz, S and Nicolini, C. 1978. Binding processes and emission spectra for acridine orange staining in the intact cell. Biophysical Society and American Physical Society Joint Meeting, March 27-30,1978, Washington, D.C.
  2. Lessin, S., Abrams, J.T., Vonderheid, E.C., Rook, A., Ju, W., Nowell, P. and DeFreitas, E. Establishment of cell lines from blood of Sezary patients requires continuous monitoring of clonality. 1988. International Symposium of Cutaneous Lymphoma. Copenhagen. October 28-30, 1988.
  3. Lessin, S.R., Huebner, K., Isobe, M., Croce, C.M. and Steinert, P.M. 1988. Chromosomal mapping of human keratin genes: evidence of non-linkage. J. Invest. Dermatol. 90(4): 581A.
  4. Steinert, P., Rothnagel, J., Idler, McKinley-Grant, L., Cannizzaro, L., Croce, C., Huebner, K. and Lessin, S. 1989. The genes for mouse and human filaggrins are polymorphic. J. Invest. Dermatol. 92(3): 522A.
  5. Lessin, S.R., Abrams, J.T., Vonderheid, E.C., Rook, A.H., Murphy, G., Ju, W.D., Nowell, P.C., and DeFreitas, E.C. 1989. Loss of clonal markers in Sezary cell lines can occur as early as 4–6 weeks in culture. Clin. Res. 37(2): 643A.
  6. Abrams, J.T., Lessin, S.R., Vonderheid, E.C., Rook, A.H., Nowell, P.C., and DeFreitas, E.C. 1989. Long-term T-cell lines established from patients with Sezary syndrome. Clin. Res. 32(2): 642A.
  7. Murphy, G.F., Abrams, J.T., Nowell, P.C., Whitaker, B.A., Lessin, S.R., Rook, A.H., Vonderheid, E.C., and DeFreitas, E.C. 1989. Ultrastructural diversity of Sezary cells in vivo and in vitro. Lab Invest. 60(1):64A.
  8. Lessin, S.R., Rook, A.H., and Rovera, G. 1990. Molecular diagnosis of cutaneous T-cell lymphoma (CTCL): Development of a molecular probe specific for a patient's malignant T lymphocytes. J. Invest. Dermatol. 94(4): 548A.
  9. Lessin, S.R., Rook, A.H., and Rovera, G. 1990. Molecular cloning of human T-cell antigen receptor beta chain gene rearrangements through polymerase chain reaction amplification. Clin. Research 38(3): 217A.
  10. Lessin, S.R., DiLosa, R.M., Benoit, B., Jaworsky, C. and Rovera, G. 1991. Molecular detection of malignant infiltration in uninvolved skin and lymph node in a patient with cutaneous T-cell lymphoma. J. Invest. Dermatol. 96(4): 535A.
  11. Benoit, B., Vonderheid, Rook, A.H. and Lessin, S.R. 1992. Progressive rearrangement of T-cell receptor beta chain gene in a patient with Sezary syndrome. J. Invest. Dermatol., 98(4): 597A.
  12. Vowels, B.R., Lessin, S., Cassin, M. and Rook, A.H. 1992. Quantitative polymerase chain reaction analysis of interleukin(IL)-4 and IL-5 demonstrates aberrant cytokine production in Sezary syndrome. J. Invest. Dermatol., 98(4): 614A.
  13. Pappu, R., Reginato, A., Martinez, V., Catalano, E. and Lessin, S. 1992. Systemic manifestations of Kimura's disease. Am. College of Rheumatology Annual Meeting, October 11-15, 1992, Atlanta, Ga.
  14. Schechter, N.M., Lessin, S.R., Wang, Z-m, Rubin, H., Blatcher, R.W., and Lazarus, G.S. 1992. Identification on mRNA specific for connective tissue mast cells in skin from an infant born with cutaneous mastocytosis. Clin. Research 40(2): 239A.
  15. S.R. Lessin, B. Benoit, C. Jaworsky, B.R. Vowels and A.H. Rook. 1993. Skin as a reservoir of minimal residual disease in cutaneous T-cell lymphoma after complete clinical response to biological response modifier therapy. J. Invest. Dermatol., 100(4): 507A
  16. Vowels, B.R., Cassin, M., Lessin,S.R., B.M. Benoit and Rook, A.H. 1993. Type 2 T-helper (Th2) cell cytokine mRNA patterns are present in the skin of cutaneous T-cell lymphoma patients. J. Invest. Dermatol., 100(4): 522A.
  17. Vowels, B.R., Lessin,S.R, Cassin, M., B.M. Benoit and Rook, A.H. 1993. Normalization of cytokine secretion patterns and immune function following disappearance of malignant clone from the peripheral blood of a Sezary syndrome patient. J. Invest. Dermatol., 100(4): 556A.
  18. Vowels, B., Cassin, M., Lessin, S., Benoit, B. and Rook, A. 1993. Cutaneous and peripheral blood evidence that cutaneous T-cell lymphoma is a malignant clonal proliferation of T helper type 2 (Th2) cells. Am. Assoc. of Immunologists / Clinical Immunology Society Meeting, May 21-25,1993, Denver, Co.
  19. Lessin, S.R., Montone, K.T., Tomaszewski, J.E. and Rook, A.H. 1994. In-situ hybridization analysis of Epstein-Barr virus latency in cutaneous T-cell lymphoma and Hodgkin's disease. J. Invest. Dermatol. 102 (4): 606A.
  20. Wolfe, J.T., Chooback, L., Finn, D.T., Benoit, B.M., Jaworsky, C., Rook, A.H. and Lessin, S.R. 1994. Large cell transformation (LCT) in cutaneous T-cell lymphoma (CTCL): Demonstration of a single neoplastic T-cell clone expressing the identical T-cell receptor (TCR). J. Invest. Dermatol. 102 (4): 623A.
  21. Weinberg, J.M., Jaworsky, C., Benoit, B.M., Telegan, B., Rook, A.H. and Lessin, S.R. 1994. Genotypic analysis of circulating Sezary cells in benign and malignant erythrodermic dermatoses. J. Invest. Derm. 102 (4): 634A.
  22. Chooback, L., Weinberg, J.M. and Lessin, S.R. 1994. T-cell receptor gene rearrangement studies as a diagnostic parameter in small plaque parapsoriasis (SPP). J. Invest. Dermatol. 102 (4): 570A.
  23. Finn, D.T., Jaworsky, C., Jensen, P.J. and Lessin, S.R. 1994. Correlation between clonotypic T-cell receptor variable region (TCR-Vβ) gene expression and aberrant T-cell antigen expression in cutaneous T-cell lymphoma (CTCL). J. Invest. Dermatol. 102 (4): 570A.
  24. Kristal, L., Honig, P.J., Chooback, L. and Lessin, S.R. 1994. The clonal relationship of pityriasis lichenoides chronica and pityriasis lichenoides et variolaformis acuta. Clin. Research 42(3): 461A
  25. Lessin, S.R., Benoit, B., Chooback, L. and Zweiman, B. 1994. Skewed T-cell receptor V usage by infiltrating t-lymphocytes in allergen induced late phase reaction (LPR). J. Allergy Clin. Immunol. 93:182.
  26. Rook, A.H., Cassin, M., Lessin, S.R., Wolf, S. and Vowels, B.R. 1994. Interleukin-12 (IL-12) reverses cytokine and immune abnormalities of Sezary syndrome. J. Invest. Dermatol. 102 (4): 557A.
  27. Rook, A.H., Kang, K., Kubin, M., Cassin, M., Trinchieri, G., Lessin, S.R. and Cooper, K.D. 1994. Interleukin 12 mRNA and protein production by epidermal langerhans' cells. Clinical Research. 42 (2): 231A.
  28. Lessin, S.R., Benoit, B., Moskovitz, A. and Zweiman, B. 1995. Quantitative analysis of immunophenotyping and T-cell receptor repertoire of infiltrating T-lymphocytes in cutaneous late phase reaction (LPR). J. Allergy Clin. Immunol. 95: 384.
  29. Salhany, K.E., Wolfe, J.T., Salvatore, R., Rook, A.H. and Lessin, S.R. 1995. p53 protein expression in cutaneous T-cell lymphoma: Relationship to disease progression. Modern Pathology 8: 50A.
  30. Chooback, L., Felix, C.A., Salhany, K.E. , Wolfe, J.T., Salvatore, R, Rook, A.H. and Lessin, S.R. 1995. Overexpression of p53 protein in cutaneous T-cell lymphoma: relationship to large cell transformation and disease progression. J. Invest. Dermatol 104: 667A.
  31. Dietz, S.B., Jensen, P.J., Murphy, G.F., Lessin, S.R. 1995. The role of αEβ7 integrin (CD103) and E-cadherin in epidermotropism in cutaneous T-cell lymphoma. J. Invest. Dermatol 104: 665A.
  32. Wolfe, J., Gottlieb, S., Fox, F., Denardo, B., Macey, W., Bromley, P and Rook, A. 1995. Treatment of cutaneous T-cell lymphoma with extracoporeal photochemotherapy at the University of Pennsylvania. J. Invest. Dermatol 104: 662A.
  33. Gottlieb, S.L., Fox, F., Cassin, M., Fakharzadeh, S., Lessin, S. and Rook, A.H. 1995. Interleukin-5 expression by peripheral blood mononuclear cells in Sezary syndrome correlates with peripheral eosinophilia and suppressed by interferon alpha. J. Invest. Dermatol 104: 683A.
  34. Li, G, Vowels, B.R., Benoit, B.M., Rook, A.H. and Lessin, S.R. 1996. Failure to detect human T-lymphotropic virus type I (HTLV-I) proviral DNA in cell lines and tissues from patients with cutaneous T-cell lymphoma. J. Invest. Dermatol 106: 914A.
  35. Fox, F.E., Kubin, M., Niu, Z., Lessin, S. and Rook, A.H. 1996. IL-15 augments cell mediated cytotoxicity and T-helper type 1 (Th1) cytokine production by PBMC from patients with Sezary syndrome. J. Invest. Dermatol. 106:936A.
  36. Lessin, S.R., Fox, F.E., Li, G., Benoit, B.M., Fang, Q., Vonderheid, E.C., Olsen, E., Higgins, T., Ginsberg, R.S., Rook, A.H., Weiner, D.B. and Williams, W.V. 1997. T-cell receptor (TCR) DNA vaccination in cutaneous T-cell lymphoma. J. Invest. Dermatol. 108:571A.
  37. Li, G., Rook, A.H. and Lessin, S.R. 1997. The arteriolymphatic circulation of cutaneous T-cell lymphoma. J. Invest. Dermatol. 108:636A.
  38. Rook, A.H., Yoo., E.K., Wood, G.S, Elenitsas, R., Fox, F.E., Niu, Z., Sherman, M.L., Kao, D., Lessin, S.R. and Vonderheid. 1998. Interleukin 12 is safe and effective therapy for cutaneous T-cell lymphoma. J. Invest. Dermatol.110:679A
  39. Lessin, S.R., Fox, F.E., Rook, A.H. and Smith, L.R. 1998. T-cell receptor beta variable gene expression in mycosis fungoides/Sezary syndrome defined by automated CDR-3 length spectratyping. J. Invest. Dermatol. 110:608A
  40. Rook AH, Vonderheid EC, Yoo EK, Kao DMF, Elanitsas R, Sherman ML, Shane RB, Lessin SR, Wood GS. 1999. Interleukin-12 induces lesion regression and cytotoxic T cell responses in cutaneous T cell lymphoma. J. Invest. Dermatol. 112: 642A.
  41. French LE, Rook AH, Benoit B, Lessin SR. 2000. Identification of a monoclonal T cell population in the blood of patients with systemic sclerosis: correlation with responsiveness to photopheresis. J. Invest. Dermatol. 114:777A.
  42. Elenitsas R, Elder, DE, Xu XC, Guerry D, Mick R, Schuchter L, Lessin S, Lotan R. 2000. RXR-alpha retinoid receptors are down regulated in dysplastic nevi. Cancer Research
  43. Edward R and Lessin S. 2001. The role of nucleotide excision repair genes XPA and XPC in melanoma pathogenesis. J Invest Dermatol 117: 522A
  44. Edwards R, Barusevicius A, Wu H, Cooper H, Lessin S. 2001. Loss of heterozygosity on chromosome 17q in cutaneous malignant melanoma. J Molecular Diagnostics 3:210A.
  45. Spittle CS, Edwards RH, Clapper ML, Lessin SR. 2002. Pyrosequencing candidate biomarkers of melanoma susceptibility: high-throughput analysis of single nucleotide polymorphisms (SNPs). J Invest Dermatol. 119(1): 271A.
  46. Edwards RH, Altomare D, Lessin SR, JR Testa. . 2002. Diminished Expression of NF-2 (Merlin) in Metastatic Malignant Melanoma. J Invest Dermatol . 119 (1): 254A.
  47. Spittle CS, Clapper ML, Lessin SR. Stress-Response Genes as Biomarkers of Melanoma Susceptibility. American Association of Cancer Research 1st Annual International Meeting on Cancer Prevention, October 14-18, 2002, Boston, MA..
  48. Manne, S, Lessin, S, Conners, J, Sherburne, S, & Fasanella, N. 2003. Correlates of Dermatological skin exam among first degree relatives of melanoma patients. Annals of Behavioral Medicine 25 (suppl), S-073.
  49. Lessin SR, Steckel SD, Wu H. 2003. A phase II trial to evaluate the efficacy of topical 1% bexarotene (Targretin®) gel in patients with parapsoriasis (T0 cutaneous t-cell lymphoma). J Invest Dermatol . 121(1): A1199.
  50. Edwards RH, Ward MR, Martin AM, Brose M, Medina A, Athanasiadis G, Volpe P, Cai K, Herlyn M, Lessin SR, Wu H, Cooper HS, Weber BL. 2003. A Role for the DNA Repair Enzyme MGMT in the Pathogenesis of Cutaneous Malignant Melanoma, Journal of Molecular Diagnostics, 5: S17.
  51. Edwards RH, Ward MR, Martin AM, Herlyn M, Lessin SR, Weber BL. 2003. Promoter methylation is one mechanism for decreased expression of the DNA repair enzyme MGMT in cutaneous malignant melanoma. 94th Annual Meeting of the American Association of Cancer Research, July 11-14, 2003, Washington D.C.
  52. Spittle CS, Ross E, Clapper M, Lessin SR. Polymorphic variants of the XP genes and risk of cutaneous melanoma. American Association of Cancer Research 2nd Annual International Meeting on Cancer Prevention, October 26-30, 2003, Phoenix, Az.
  53. Lessin SR, Ross E, Clapper M, Spittle CS. 2004. XPA gene polymorphism is associated with risk of cutaneous melanoma. 65th Annual Meeting of the Society for Investigative Dermatology, April 28- May 1, 2004, Providence, RI.
  54. Edwards RH, Ward MR, Martin AM, Herlyn M, Wu H, Cooper HR, Lessin SR, Weber BL. 2004. Decreased Expression of the DNA Repair Enzyme MGMT in Cutaneous Malignant Melanoma. 95th Annual Meeting of the American Association of Cancer Research, March 27-31, 2004, Orlando, FL.
  55. Spittle C, Edwards R, Clapper M, Lessin S. 2004. Solar-stimulated UV modulation of genes associated with DNA repair in cultured human melanocytes. Third Annual American Association of Cancer Research International Conference: Frontiers in Cancer Prevention, October 16-20, 2004, Seattle, Wa.
  56. Lessin SR, Ross E, Clapper M, Spittle C. 2004. Polymorphisms in stress response genes associated with risk of cutaneous melanoma. Second International Melanoma Research Congress, November 13-16, 2004, Phoenix, Az
  57. Edwards RH, Wu H, Gimotty PA, Botbyl J, Guerry D, Cooper HS, Adams-McDonnell R, Davis W, Lessin SR, Weber BL. 2004. Phospho-ERK Expression Correlates with Stage of Progression in Melanocytic Neoplasia. Second International Melanoma Research Congress, November 13-16, 2004, Phoenix, Az
  58. Lessin SR, Steckel SD, Wu H. 2005. A phase II trial to evaluate the efficacy of topical 1% bexarotene gel in patients with parapsoriasis (T0 cutaneous t-cell lymphoma) [Final Report]. 63rd Annual Meeting of the American Academy of Dermatology, February 18-22, 2005, New Orleans, La.
  59. Edwards RH, Altomare DA, Spittle CS, DeVos ML, Ward MR, Lessin SR, Weber, B, Testa. JR. 2005. Identification of mutations in the NF2 gene in cutaneous malignant melanoma. 96th Annual Meeting of the American Association of Cancer Research, April 16-20, 2005. Anaheim, Ca.
  60. Lessin SR, Ross E, Clapper M, Spittle CS. 2005. Assessing DNA repair capacity as a marker of melanoma risk: polymorphisms and gene expression in stress response genes. 66th Annual Meeting of the Society for Investigative Dermatology, May 4-7, 2005, St. Louis, Mo.
  61. Wu H, Xu X-Z, Dadke S, Spittle C, Lessin SR. 2006. Cortactin, defining its role in melanocytic tumor progression. 67th Annual Meeting of the Society for Investigative Dermatology, May 3-6, 2006, Philadelphia, Pa. J Invest Dermatol 126(4) supplement 146a, 2006.
  62. Lessin, SR. 2007 Nitrogen mustard (NM) ointment formulation containing propylene glycol (PG) is active in treating mycosis fungoides (MF). J Invest Dermatol 127 supplement 1, S42.
  63. Lessin SR, Duvic M, Strober BE, Rook AH, Kim EJ, Olsen EA, Walker BR, Kim YH. 2007. Testing efficacy and safety of topical nitrogen mustard in mycosis fungoides. 21st World Congress of Dermatology, October 3, 2007. Buenos Aires, Argentina
  64. Edwards RH, Spittle CS, Quesnelle K, Rooney R, Gimotty PA, Hammond R, Brose M, Lessin SR, Herlyn M. 2007. Characterization of UV-induced signaling patterns in melanocytes and malignant melanoma. J Invest Dermatol 127 supplement 1, S154.
  65. Xu X-Z, Spittle C, Varella-Garcia M, Edwards R, Lessin S, Wu H. 2007. Cortactin, a cytoskeleton-associated adaptor protein, in melanocytic tumor progression. J Invest Dermatol 127 supplement 1, S152.
  66. H Wu, J Seykora & S Lessin. Localized telogen effluvium secondary to underlying temporal arteritis. 46th Annual Meeting of the American Society of Dermatopathy October 1-4, 2009. Chicago, IL.
  67. Xu-Zhi Xu, Marileila Varella Garcia, Tian-yu Li, Li-Yan Khor, R. Sujatha Gajapathy, Cindy Spittle, Scott Weed, Stuart R. Lessin, Hong Wu. Cytoskeleton alterations in melanoma: Aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression. VI International Melanoma Congress, Nov 1-4, 2009. Boston Ma.
  68. CM Shaw, F Zhu, SR Lessin, ER Sigurdson. Effect of Body Mass Index on Overall Survival in Patients with Locoregionally Advanced Melanoma. Society of Surgical Oncology Annual Cancer Symposium. March 3-7, 2010. St. Louis, Mo.
  69. S Manne, P Jacobsen, S Lessin, M Ming, G Winkel. Generic versus Tailored Interventions for Multiple Skin Cancer Risk Reduction Practices for Family Members of Melanoma Patients. 31st Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine. April 7-10, 2010. Seattle, Wa.
  70. Lessin-SR, Duvic-M, Guitart-J, Pandya-A, Strober-BE, Olsen-EA, Hull-CM , Knobler-EH, Rook-AH, Kim-EJ, Naylor-MF, Adelson-DM, Kimball-AB, Wood-GS, Wu-H, Walker-BR, Kim-YH . A randomized, pivotal trial to evaluate the safety & efficacy of 0.02% nitrogen mustard formulations in patients with stage I or IIa mycosis fungoides. First World Congress for Cutaneous Lymphomas, September 22-25, 2010, Chicago, IL.
  71. Kantekure-K, Al-Saleem-T, Lessin-SR, Wu-H. Flow cytometry in the diagnosis of cutaneous lymphoid lesions. First World Congress for Cutaneous Lymphomas, September 22-25, 2010, Chicago, IL.
  72. Hodak E, Lessin S, Friedland R, David M, Cohen A. Associated co-morbidities in patients with mycosis fungoides. First World Congress for Cutaneous Lymphomas, September 22-25, 2010, Chicago, IL.
  73. Siripurapu V, Shaw C, Anderson PR, Perlis CS, Topham NS, Wu H, von Mehren M, Lessin SR, Farma JM. Dermatofibrosarcoma protuberans with fibrosarcomatous transformation: analysis of outcomes. Connective Tissue Oncology Society Annual Meeting, November 11-13, 2010, Paris, France.
  74. Lessin-SR, Duvic-M, Guitart-J, Pandya-A, Strober-BE, Olsen-EA, Hull-CM , Knobler-EH, Rook-AH, Kim-EJ, Naylor-MF, Adelson-DM, Kimball-AB, Wood-GS, Wu-H, Walker-BR, Kim-YH . A Pivotal Phase II Trial Demonstrating the Safety and Efficacy of a Manufactured 0.02% Nitrogen Mustard Gel in Mycosis Fungoides. 22nd World Congress of Dermatology, May 24-29, 2011, Seoul, Korea.
  75. Lessin SR. Topical Mechlorethamine (Nitrogen Mustard) in Mycosis Fungoides / Cutaneous T-cell Lymphoma: A Long Journey to Approval. 131st Annual Meeting of the American Dermatological Association, September 14-18, 2011, Napa, CA.
  76. YH Kim, M Duvic, J Guitart, SR Lessin. Tolerability and Efficacy of Mechlorethamine 0.04% Gel in CTCL (Mycosis Fungoides) after Initial Treatment with Topical Mechlorethamine 0.02% Gel: 6th Annual T-Cell Lymphoma Forum, January 23-25, 2014 San Francisco, CA.
  77. Povidone iodine nail solution is active in treating onychomysis Capriotti K, Capriotti J, Lessin S. 2014. Povidone iodine nail solution is active in treating onychomysis. J Am Acad Derm 70(5): AB118
  78. Capriotti K, J, Capriotti, LaCouture M, Lessin S, Belum V. 2014. Paronychia requiring intervention in patients receiving taxanes: A review of the literature. J Am Acad Derm 70(5):AB118
  79. Kim, YH, Duvic M, Guitart J, Lessin SR. Efficacy and Safety of Mechlorethamine (MCH) 0.04% Gel in Mycosis Fungoides (MF) after Treatment with Topical MCH 0.02%. 50th Annual Meeting of the American Society of Clinical Oncology. May 30 – June 3, 2014. Chicago, IL.